Author's response to reviews

Title: Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study

Authors:

Eytan M Debbi (eytan.debbi@aya.yale.edu)
Gabriel Agar (gabyagar@gmail.com)
Gil Fichman (gil_fichman@hotmail.com)
Yaron Bar Ziv (ybarziv@013.net.il)
Rami Kardosh (kardosh27@hotmail.com)
Nahum Halperin (nhalpern@post.tau.ac.il)
Avi Elbaz (avie@apos.co.il)
Yiftah Beer (yiftah.beer@gmail.com)
Ronen Debi (debbi.ronen@gmail.com)

Version: 4 Date: 2 June 2011

Author's response to reviews: see over
Dear Sir\Madam,

Thank you for the most recent review of our paper, entitled, “Efficacy of methylsulfonylmethane supplementation on osteoarthritis of the knee: a randomized controlled study” [MS: 1312127821487565].

Below is a point-by-point response to the additional changes to the format of the manuscript. The changes are highlighted in yellow in the manuscript itself and are cited below.

We thank you again for the reconsideration of our work.

Sincerely yours,

Ronen Debi, MD
1. Equal contributors- Please note that we can only allow two equal contributors on the title page, please revise the author details as necessary.

The author details were revised as needed. Only two equal contributors were included on the title page.

2. Abstract - The trial registration number must be mentioned in the abstract. The last section of the abstract must be titled Trial Registration: listing the trial registry and the unique identifying number. Please note that there must be no space between the letters and numbers of the trial registration number e.g. ISRCTN12345678.

The trial registration number was added to the end of the abstract as follows:

“Trial Registration: NIH clinical trial registry NCT01188213”

3. Competing interests: Please declare under this section that the placebo was donated by Ta’am Teva as well as any other involvement by this company on this study.

The following was added to the competing interests section:

“The MSM and placebo used in the study were donated by the manufacturer Ta’am Teva. Ta’am Teva had no other involvement in the study.”